MX2023001883A - Compuestos heteroarilicos sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9). - Google Patents

Compuestos heteroarilicos sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9).

Info

Publication number
MX2023001883A
MX2023001883A MX2023001883A MX2023001883A MX2023001883A MX 2023001883 A MX2023001883 A MX 2023001883A MX 2023001883 A MX2023001883 A MX 2023001883A MX 2023001883 A MX2023001883 A MX 2023001883A MX 2023001883 A MX2023001883 A MX 2023001883A
Authority
MX
Mexico
Prior art keywords
sub
tlr9
inhibitors
substituted heteroaryl
compounds useful
Prior art date
Application number
MX2023001883A
Other languages
English (en)
Spanish (es)
Inventor
Alicia Regueiro-Ren
Chunjian Liu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023001883A publication Critical patent/MX2023001883A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2023001883A 2020-08-19 2021-08-18 Compuestos heteroarilicos sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9). MX2023001883A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063067389P 2020-08-19 2020-08-19
PCT/US2021/046475 WO2022040293A1 (en) 2020-08-19 2021-08-18 Substituted heteroaryl compounds useful as inhibitors of tlr9

Publications (1)

Publication Number Publication Date
MX2023001883A true MX2023001883A (es) 2023-03-10

Family

ID=77726550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001883A MX2023001883A (es) 2020-08-19 2021-08-18 Compuestos heteroarilicos sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9).

Country Status (16)

Country Link
US (1) US20230322770A1 (https=)
EP (1) EP4200015B1 (https=)
JP (1) JP2023539136A (https=)
KR (1) KR20230052930A (https=)
CN (1) CN115956077A (https=)
AR (1) AR123284A1 (https=)
AU (1) AU2021328362A1 (https=)
BR (1) BR112023002662A2 (https=)
CA (1) CA3189816A1 (https=)
CL (1) CL2023000428A1 (https=)
CO (1) CO2023001670A2 (https=)
IL (1) IL300696A (https=)
MX (1) MX2023001883A (https=)
PE (1) PE20231318A1 (https=)
TW (1) TW202227431A (https=)
WO (1) WO2022040293A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI838670B (zh) * 2020-12-22 2024-04-11 美商基利科學股份有限公司 經取代之吲哚化合物
TWI887510B (zh) * 2020-12-22 2025-06-21 美商基利科學股份有限公司 6-取代之吲哚化合物
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
KR20240148414A (ko) * 2022-02-18 2024-10-11 브리스톨-마이어스 스큅 컴퍼니 Tlr9의 억제제로서 유용한 치환된 이미다조피리디닐 화합물
WO2024102886A1 (en) * 2022-11-10 2024-05-16 Bristol-Myers Squibb Company Substituted benzimidazole compounds useful as inhibitors of tlr9
CN120152957A (zh) * 2022-11-10 2025-06-13 百时美施贵宝公司 用作tlr9抑制剂的经取代的喹诺酮

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158049A1 (en) * 2011-12-20 2013-06-20 Hoffmann-La Roche Inc. 7-azaindole inhibitors of crac
EP3080124A1 (en) * 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
AR103232A1 (es) * 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
FI3728252T3 (fi) * 2017-12-18 2023-10-18 Bristol Myers Squibb Co 4-atsaindoliyhdisteitä
WO2019126082A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company 6-azaindole compounds
CA3085942A1 (en) * 2017-12-20 2019-06-27 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds

Also Published As

Publication number Publication date
AU2021328362A1 (en) 2023-03-23
AR123284A1 (es) 2022-11-16
US20230322770A1 (en) 2023-10-12
WO2022040293A1 (en) 2022-02-24
IL300696A (en) 2023-04-01
CO2023001670A2 (es) 2023-02-27
CL2023000428A1 (es) 2023-07-28
JP2023539136A (ja) 2023-09-13
KR20230052930A (ko) 2023-04-20
CN115956077A (zh) 2023-04-11
EP4200015A1 (en) 2023-06-28
TW202227431A (zh) 2022-07-16
EP4200015B1 (en) 2026-04-29
CA3189816A1 (en) 2022-02-24
BR112023002662A2 (pt) 2023-03-14
PE20231318A1 (es) 2023-08-24

Similar Documents

Publication Publication Date Title
MX2023001883A (es) Compuestos heteroarilicos sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9).
JOP20220101A1 (ar) مثبطات صغيرة الجزئ لطافر G12C لبروتين ساركوما جرذان Kirsten (KRAS)
CR20210602A (es) Compuestos de pirrolidina
WO2024123913A8 (en) Kras(g12v) inhibitors
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
PH12022550029A1 (en) Deuterated mk2 pathway inhibitors and methods of using the same
EA200970535A1 (ru) Антибактериальные производные хинолина
EP1467970A4 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
WO2001064639A3 (en) Pde iv inhibiting amides, compositions and pharmaceutical use
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
MX2023011408A (es) Compuestos de oxoisoindolina sustituidos con piridinilo para el tratamiento de cancer.
MX2020011317A (es) Compuestos heterociclicos triciclicos utiles como inhibidores de la integrasa de vih.
WO2021030379A9 (en) Bicyclic heteroaryl compounds useful as irak4 inhibitors
MX2024001417A (es) Compuestos de heteroarilo para tratar la enfermedad de huntington.
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA200970534A1 (ru) Антибактериальные производные хинолина
MX389581B (es) Compuestos que contienen nitrogeno sustituido.
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
MX2022011565A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
MX2024013095A (es) Compuestos inhibidores de fgfr2
MX2024014435A (es) Compuestos heterociclicos y heteroarilo para el tratamiento de la enfermedad de huntington
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2025013372A (es) Inhibidores de gsk3\03b1 y metodos de uso de estos
DE60322919D1 (de) 8-hydroxy-1-oxotetrahydropyrrolopyrazinverbindungen, die sich als inhibitoren von hiv-integrase eignen